New oral pill aims to clear psoriasis in major trial
NCT ID NCT07672561
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 3 study tests whether the experimental drug WD-890 can safely improve skin clearance in adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either WD-890 or a placebo tablet daily for up to 52 weeks. The main goals are to see if more people achieve clear or almost clear skin and at least a 75% reduction in psoriasis severity by week 16.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WD-890
What this could lead to
If successful, WD-890 could offer a new oral treatment option for people with moderate to severe plaque psoriasis, potentially improving skin clearance and quality of life.
What could go wrong
This is a phase 3 trial, but results may not confirm efficacy or safety. The drug could cause side effects or fail to outperform placebo. Long-term risks are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital of Dermatology, Chinese Academy of Medical Sciences
RECRUITINGNanjing, Jiangsu, 210042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••